The company’s strategic changes include a staff reduction, Cellaviva becoming a wholly owned subsidiary and the GMP facility will have new sources of revenue. NextCell develops the cell therapy drug
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
The Biomedical Center (BMC) will have improved study spaces, greener courtyards, more energy measures, more welcoming entrances and a new clinical training centre. BMC, located in the southern parts of
The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Aurealis Therapeutics’ lead product candidate AUP-16 for the treatment of non-healing Diabetic Foot Ulcers (nhDFU). “With the PRIME
Jacob Tolstrup, Executive Vice President, Commercial Operations will leave Lundbeck no later than March 1, 2024. Jacob Tolstrup joined Lundbeck in 1999 and has held various management positions across the company, becoming
The network, established by Umeå Biotech Incubator, brings together representatives from some 15 companies, focuses on sharing experiences and strategies to deal with the increasingly complex quality requirements facing the
InDex Pharmaceuticals will discontinue development of their drug candidate cobitolimod. Thorough analysis of the data from Induction Study 1 of the phase III program CONCLUDE has not provided any results
The board of directors of Kancera has resolved on a new share issue with preferential rights for the company’s existing shareholders of approximately SEK 121.9 million. The objective of the
Gunilla Osswald, CEO, BioArctic, has been awarded The Arthur D. Little Nordic Life Science Award 2024. The award is given to people in the Nordics who demonstrate exceptional leadership within
A report jointly published by the AllTrials campaign, Cochrane Denmark, Cochrane Norway, Cochrane Sweden, the Dam Foundation, Melanomföreningen, and TranspariMED, shows that 475 clinical trials involving 83,903 patients completed during
The first human patient implanted with a brain-chip from Neuralink appears to have fully recovered and is able to control a computer mouse using their thoughts, stated Elon Musk late
NEOGAP Therapeutics has been granted a patent in Australia for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS). The patent strengthens NEOGAP’s
Orion Corporation is evaluating the possible outsourcing of its pharmaceutical production in Kuopio, part of its Global Operations function, to an entity outside Finland. The basis for the possible outsourcing
Ultimovacs has announced that the European Medicines Agency (EMA) has issued a positive opinion on the company’s application for Orphan Drug Designation (ODD) for its therapeutic cancer vaccine UV1 for
Sponsored content
Cell and Gene Therapy Developers: This Is What Your Logistics Provider Must Do
In this article, John Coleman, Business Unit Director at ATMP logistics provider YSDS Life Science, explores the crucial role of logistics providers in ensuring the seamless transport of ATMPs in while adhering to the standards for an optimal vein-to-vein process.
ACELYRIN has announced that the global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met its primary endpoint with high statistical significance. Positive long-term data from a Phase
The combined treatment of UV1 with ipilimumab and nivolumab showed similar clinical benefits as treatment with ipilimumab and nivolumab alone, meaning the primary and secondary endpoints of the study were
The Board of the national non-profit association for the life science industry in Sweden, SwedenBIO, has appointed Helena Strigård as their new CEO. Strigård will start her new position on
Careers
In 1987, Per-Anders Jansson obtained his medical degree and started working as a physician, mainly focusing on diabetes. For the last 25 years, he has devoted his life to learning
JOB ALERTS
Read the latest issue of our magazine!
No 01 2024 // Many scientists state that we are entering the golden age of CNS disease treatment. Learn more about some of the most recent progress being made within the field, including Nordic advances. This issue’s profile is professor Mia Phillipson, co-founder of Ilya Pharma, co-director at SciLifeLab, a member of the Royal Swedish Academy of Sciences, and a scientist pioneering immunotherapies. We have a special report on the life science financial landscape, including VC predictions for 2024, an interview with Thomas Eldered, Flerie Invest, and a global outlook. This issue also includes a special focus on the skills shortages within cell and gene therapy manufacturing, startup advice and what it is like to work as a Bioprocess Engineer.
The latest research news from the Nordic region
Nordic Life Science
The latest clinical trials
Sign up to our newsletter